PH1-61 A PHASE 1 STUDY OF ABT-888 IN COMBINATION WITH CARBOPLATIN AND PACLITA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是确定ABT-888 II期研究的推荐剂量，该剂量可与卡铂和紫杉醇联合用于晚期实体瘤患者。ABT-888和紫杉醇剂量将递增。将定义DLT和其他毒性。将进行PK和分子相关性研究。ABT-889在第1-7天口服，每日两次。第3天给予卡铂和紫杉醇。USC将不参与MTD阶段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to determine the recommended dose for phase 2 studies of ABT-888 that can be given with carboplatin and paclitaxel in patients with advanced solid tumors. ABT-888 and paclitaxel doese will be escalated. The DLT and other toxicities will be defined. PK and molecular correlates will be done. ABT-889 is given orally bid on days 1-7. Carboplatin and paclitaxel will be given on day 3. USC will not participate in the MTD phase.